Launch Excellence · Rare Disease · EU Markets
Why Rare Disease Launches
Fail in the EU
The structural reasons most EU rare disease launches miss their
first-year forecast and what changes the trajectory.
phamax Launch Excellence Practice     |      August 2026     |      8 min read     |     2,500+words
Most rare disease launches in the EU miss their first-year forecast. The reasons are structural, not executional. Better field deployment, improved CRM coverage, or faster reporting cycles will not fix a launch that was built on the wrong commercial foundation. The problems that determine launch trajectory are set years before the first patient receives treatment and in the EU, they are compounded by a level of market complexity that most conventional launch models were never designed to handle.
This is what we have seen across 60+ rare disease engagements in EU markets. It is also what the data consistently shows.
The Scale of the Opportunity and the Weight of Expectation
The EU rare disease treatment market generated revenue of USD 37.4 billion in 2025 and is projected to reach USD 88.2 billion by 2033, growing at a CAGR of 11.1% over that period. Europe currently represents 17.3% of the global rare disease treatment market, with France expected to register the highest country-level growth rate through 2033 (Grand View Research, 2026).
$37.4B
EU rare disease treatment market revenue in 2025
Grand View Research, 2026
$88.2B
Projected EU market size by 2033 at 11.1% CAGR
Grand View Research, 2026
350M
People worldwide living with a rare disease
IQVIA, May 2026
95%
Of rare diseases still have no approved treatment
Global Genes, 2024
The societal and economic burden is estimated at $1.25 trillion annually across the US and Europe, encompassing direct medical costs alongside indirect costs including lost productivity and caregiver strain (IQVIA, May 2026; Yang et al., 2022). Driven by unmet need and advances in science, orphan drugs are projected to make up 21% of global prescription drug sales by 2032, reaching approximately $409 billion at a 10% CAGR (IQVIA, May 2026).
The investment case is clear. But the execution gap is just as clear, and it is widening.
Why EU Rare Disease Launches Are Structurally Different
That shift changes everything about how a launch must be designed and executed.
​
In rare disease, you are not launching into a defined market with known prescriber bases, established referral pathways, and comparable analogs from similar launches. You are building commercial infrastructure for a disease that most treating physicians may see only one or two patients with in their careers. The patient population is fragmented across geographies, the diagnostic pathway is often unclear or delayed, and the evidence base required by EU healthcare decision-makers goes well beyond what clinical trials alone can provide.
​
The rapid ascendancy of speciality and orphan drugs has also fundamentally changed the commercial model. Traditional broad-based promotional strategies have lost traction. The focus is now on high-level scientific dialogue, key account management, and value-based contracting. Launch teams are smaller, working across more assets, in more rapid succession with less margin for error at each stage (Tribeca Knowledge).
Â
Three structural factors make EU rare disease launches particularly vulnerable.
The pharmaceutical industry is "arguably a victim of its own success." Diseases that previously exerted a huge toll on society - diabetes, asthma, and many cancers - are now generally well controlled. Industry now has to focus on "the most complex, difficult-to-treat, niche patient populations and/or diseases which are poorly understood.
Karen Young, Senior Research Manager, Deloitte Centre for Health Solutions
The Three Structural Failure Patterns
1. The Framework and Alignment Gap
Â
Most rare disease launch failures do not begin at launch. They begin 18 to 24 months earlier, when the commercial hypothesis is being formed without a consistent framework that connects global strategy to country-level execution.
​
IMS Health (now IQVIA) identified alignment as one of the three defining factors of launch excellence specifically, alignment between global and local teams, and between clinical and commercial functions. The failure modes are predictable: information lags, lack of clarity over timelines and KPIs, fragmentation of resources, strategic misalignment, and last-minute reversals to the launch plan (IMS Health Launch Excellence Framework).
​
The consequences of a pricing or reimbursement difficulty in one EU market reverberate across all others. Country-to-country reference pricing means a poorly negotiated first submission in Germany or France sets a ceiling for every subsequent market. Most launch teams understand this in principle. Far fewer have a framework in place that operationalises it before the first submission is filed.
Failure mode 01
Framework and Alignment
Â
EU affiliates are often small, under-resourced, and managing multiple launch assets simultaneously. When the global launch framework does not translate clearly into country-level priorities, affiliates default to reporting on activity rather than driving the decisions that change patient access outcomes.
2. The Patient Pathway Visibility Gap
Â
In rare disease and specialty care, the primary barrier to uptake is rarely field execution or reimbursement status. It is patient identification.
​
The HCP who diagnoses a rare disease is often not the HCP who treats it. In conditions such as haemophilia, lysosomal storage disorders, or hereditary angioedema, the diagnostic pathway involves multiple specialists across years before a patient reaches a treatment centre. Without a validated map of that pathway built from primary research with both HCPs and patients the commercial model is targeting the wrong point in the system (Axtria / Vipul Pandey).
​
A brick-level analysis of a rare disease oncology launch in Germany identified three regional clusters where patient opportunity was significantly higher than performance suggested. The primary cause was not field underperformance. It was diagnostic pathway readiness the referral infrastructure to get patients from identification to treatment was not in place at launch. Redirecting commercial investment based on that finding produced measurable improvement in uptake within one planning cycle.
​
This kind of analysis requires patient pathway data, not just sales data. Most EU launches go into market without it.
Failure mode 02
Patient Pathway Visibility
​
When phamax connects sales data, patient opportunity estimates, access status, and diagnostic referral patterns at a regional level, high-opportunity areas are consistently being suppressed not by lack of field coverage but by structural gaps in the patient pathway. The diagnostic pathway is the bottleneck, not the commercial one.
3. The Global-Local Disconnect
Â
Most rare disease launches are planned globally and executed locally, with a gap between the two that widens with every country added to the programme.
​
The KOL landscape in rare disease is narrow and non-uniform across EU markets. The five or six specialists who drive disease state awareness and patient identification in Germany are not the same five or six who matter in France or the Nordics. Global KOL mapping does not translate to local engagement without country-level relationship intelligence.
​
Measurement frameworks are typically defined at global level without the granularity to detect early signals at country or regional level. By the time a problem shows up in national sales data, the first six months of launch are gone — and the window that determines long-term trajectory has closed.
​
​
Failure mode 03
Global-Local Disconnect
​
A product approved by the EMA does not become commercially available to patients in Germany, France, and the Netherlands on the same date or under the same conditions. Each market has its own HTA process, its own evidence requirements, and its own pricing negotiation dynamic. Launching without country-specific access intelligence built into the commercial model means the forecast is wrong before day one.
The Cost of Getting
This Wrong
$15M
The commercial consequence is severe. A delayed or underperforming rare disease launch is not a recoverable situation in the way that a mass-market launch sometimes can be. Patient populations are small, treatment centres are few, and HCP prescribing behaviour in rare disease once established is difficult to change. If a competitor reaches key accounts and builds clinical relationships first, the structural disadvantage compounds over years.
Â
In rare disease, the first-mover gap is not simply competitive. It is patient access. Every month of delayed uptake in a rare disease is a month in which eligible patients are not receiving treatment (Tribeca Knowledge / McKinsey via SmartLaunch).
40%
The six-month window is not a figure of speech. 80% of launches continue as they start in the first six months. Most launches have only one shot at establishing the trajectory that determines long-term performance.
Average cost of a delayed launch, per drug per day.
Market share held by first entrants at 10 years vs 33% for second.
1.0%
IRR reduction from one year's launch delay (Deloitte).
What We Have Seen Across 60+ EU Rare Disease Projects
phamax has delivered rare disease commercial consulting across more than 60 EU engagements since 2014, covering haemophilia, lysosomal storage disorders, muscular dystrophy, hereditary angioedema, primary sclerosing cholangitis, and oncology across six indications including breast cancer, gastric cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer (NSCLC and SCLC), and pancreatic cancer.
Across that body of work, three observations hold consistently.
01
The launches that perform are those where the patient pathway was mapped and validated before commercial deployment, not after.Â
Understanding where patients are lost in the diagnostic and referral journey, which specialties are involved, which treatment centres are under-served, which regions have the infrastructure to identify and refer eligible patients is not a secondary research task. It is the foundation of a commercial model that can actually work.
02
The launches that underperform share one characteristic more than any other: the commercial model was built at global level and applied at country level without sufficient local evidence. Â
EU markets are not interchangeable. Germany's benefit assessment under AMNOG, France's SMR/ASMR rating, and NICE's highly specialised technologies pathway each require different evidence packages, different timing strategies, and different stakeholder engagement approaches. A launch plan that treats EU market entry as a single event is structurally misaligned before it begins.
03
Post-launch variance, when it appears, is almost always explained by access or pathway factors, not field factors.Â
When phamax connects sales data, patient opportunity, access status, and field activity at regional and account level, the root cause of performance gaps is consistently structural diagnostic pathway readiness, access milestone timing, or institutional adoption dynamics rather than insufficient field effort.
How phamax Approaches Launch Readiness in EU Rare Disease Markets
Our starting point is always the evidence, not the assumption. Before any commercial recommendation is made, we structure the available information patient epidemiology, diagnostic pathway data, HCP referral patterns, access conditions by country, and field activity into a single coherent picture. Where evidence gaps exist, we name them explicitly and establish what additional intelligence is needed before a reliable recommendation can be made. This is what we mean by an evidence-based commercial hypothesis: not a forecast built on analogs, but a structured view of the opportunity grounded in what is actually known about the specific disease, the specific markets, and the specific patient population.
​
Before recommending a launch sequence
or access strategy, phamax conducts
a structured PEST analysis across each
target EU market
Dimension
What we map
[P]olitical & Regulatory
HTA requirements, pricing policy, reimbursement pathways, orphan designation status
[E]conomic
Healthcare budget constraints, spending priorities, reference pricing interdependencies across EU markets
[S]ocial
Patient advocacy strength, disease awareness levels, diagnostic infrastructure, patient pathway maturity
[T]echnological
Data availability by country, digital health adoption, real-world evidence requirements, registry infrastructure
This gives the commercial team a country-by-country view of where the access environment is favourable, where it is restrictive, and what the launch sequence should be as a result. Answering these questions early with the right data and with experienced EU rare disease consultants challenging every assumption is what makes the difference between a launch that builds momentum from day one and one that spends its first six months recovering from a misaligned foundation.
​
For teams already in market, our post-launch diagnostic connects the same data sources sales, patient opportunity, access status, diagnostic referral patterns, and field activity to explain performance variation at a level national reporting cannot reach. The output is not a report. It is a prioritised action plan: which regions, institutions, and patient pathways to focus on, why, and what to do differently in the next planning cycle.
What Changes the Trajectory
Most rare disease launch failures are not surprises in retrospect. The signals are present in the data, in the patient pathway, and in the access environment long before they show up in national sales figures. The question is whether the commercial team has the infrastructure to see them early enough to act.
​
What changes the trajectory is not a better dashboard. It is connecting the right data patient opportunity, access conditions, diagnostic pathway structure, and field activity into one coherent view, early enough in the launch cycle that the planning window is still open.
​
The six-month window means there is no second chance to establish the trajectory that determines long-term performance. The structural work patient pathway mapping, access evidence building, country-level commercial design has to be done before launch day, not in response to underperformance after it.
​
For organisations preparing for an EU rare disease launch, or seeking to understand why a current launch is not tracking to plan, the starting point is always the same question: do you know where your patients are, and do you know what is preventing them from reaching treatment?
This blog draws on published research from IQVIA, Grand View Research, Tribeca Knowledge / SmartLaunch, Axtria, Global Genes, and Deloitte. phamax does not claim proprietary rights to third-party data cited herein. All external statistics are attributed to their original sources.
REFERENCES
Â
-
IQVIA. Rare Diseases, Bold Strategies. May 2026. iqvia.com
-
Global Genes. Rare Disease Facts. 2024. globalgenes.org
-
Yang G, Cintina I, Pariser A, et al. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17:163.
-
Grand View Research. Europe Rare Diseases Treatment Market Size & Outlook, 2026–2033. grandviewresearch.com
-
Tribeca Knowledge / SmartLaunch. Launch Readiness. tribecaknowledge.com
-
Axtria / Vipul Pandey. Evaluation of Marketing Strategies for Rare Diseases. axtria.com
-
IMS Health Consulting. IMS Launch Excellence Framework. Source: Tribeca Knowledge.